Loading...
•
Mar 31, 2024
Zai Lab Q1 2024 Earnings Report
Announced first quarter 2024 financial results with strong commercial execution and pipeline progress.
Key Takeaways
Zai Lab reported a strong first quarter in 2024, with net product revenue of $87.1 million, representing 39% year-over-year growth (43% at CER). The launch of VYVGART contributed $13.2 million in sales. The company is preparing for potential launches and expects significant revenue growth and profitability by the end of 2025.
Net product revenue reached $87.1 million, a 39% increase year-over-year (43% at CER).
VYVGART sales amounted to $13.2 million, driven by increased patient access.
Regulatory reviews are ongoing for sulbactam-durlobactam, efgartigimod SC, and repotrectinib.
Cash position remains strong at $750.8 million as of March 31, 2024.
Zai Lab
Zai Lab
Zai Lab Revenue by Segment
Revenue by Segment
VYVGART and VYVGART Hytrulo Revenue
CapyFin.comZEJULA Revenue
CapyFin.comNUZYRA Revenue
CapyFin.com Forward Guidance
Zai Lab anticipates potential NMPA approval of NDA for ROS1-positive NSCLC. They also anticipate topline data readout from the Phase 3 PANOVA-3 clinical trial in locally advanced pancreatic cancer in Q4 2024. Zai Lab expects potential dose escalation data from the global Phase 1 study in relapsed and refractory second-line+ SCLC at the end of 2024 or early 2025.
Positive Outlook
- Potential NMPA approval of NDA for ROS1-positive NSCLC.
- Zai Lab to submit a Marketing Authorization Application (MAA) to the NMPA in second-line+ NSCLC.
- Novocure to provide a topline data readout from the Phase 3 PANOVA-3 clinical trial in locally advanced pancreatic cancer in the fourth quarter of 2024.
- Potential dose escalation data from the global Phase 1 study in relapsed and refractory second-line+ SCLC at the end of 2024 or early 2025.
- Zai Lab to initiate a global Phase 2 study in mild-to-moderate chronic plaque psoriasis in the second quarter of 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income